HRP20191306T1 - Postupak proizvodnje lijekova - Google Patents
Postupak proizvodnje lijekova Download PDFInfo
- Publication number
- HRP20191306T1 HRP20191306T1 HRP20191306TT HRP20191306T HRP20191306T1 HR P20191306 T1 HRP20191306 T1 HR P20191306T1 HR P20191306T T HRP20191306T T HR P20191306TT HR P20191306 T HRP20191306 T HR P20191306T HR P20191306 T1 HRP20191306 T1 HR P20191306T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvent
- give
- ketoreductase
- agent
- strong base
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000003814 drug Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 8
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 claims 8
- 239000003960 organic solvent Substances 0.000 claims 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 6
- 239000003880 polar aprotic solvent Substances 0.000 claims 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 4
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims 4
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical group [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- ZNGGAPYUQROFJC-QMMMGPOBSA-N (1r)-1-(4-chloro-3-fluorophenyl)ethane-1,2-diol Chemical compound OC[C@H](O)C1=CC=C(Cl)C(F)=C1 ZNGGAPYUQROFJC-QMMMGPOBSA-N 0.000 claims 3
- ATHKVJCNHIGEBV-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)-2-hydroxyethanone Chemical compound OCC(=O)C1=CC=C(Cl)C(F)=C1 ATHKVJCNHIGEBV-UHFFFAOYSA-N 0.000 claims 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical group CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- FRSBDALHVZFPHT-UHFFFAOYSA-N 2-chloro-1-(4-chloro-3-fluorophenyl)ethanone Chemical compound FC1=CC(C(=O)CCl)=CC=C1Cl FRSBDALHVZFPHT-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000000010 aprotic solvent Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical group COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims 3
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical group [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 claims 3
- 238000004064 recycling Methods 0.000 claims 3
- RAEXTEKKMYSCEX-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)C1=CC(NC=C1)=O Chemical compound CS(=O)(=O)C1=NC=CC(=N1)C1=CC(NC=C1)=O RAEXTEKKMYSCEX-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 claims 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SCOJKGRNQDKFRP-UHFFFAOYSA-N 2-chloro-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CCl SCOJKGRNQDKFRP-UHFFFAOYSA-N 0.000 claims 1
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 claims 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000698 Formate Dehydrogenases Proteins 0.000 claims 1
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 claims 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims 1
- 108010020056 Hydrogenase Proteins 0.000 claims 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims 1
- 108010036197 NAD phosphite oxidoreductase Proteins 0.000 claims 1
- 239000004280 Sodium formate Substances 0.000 claims 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 238000005828 desilylation reaction Methods 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- QARBMVPHQWIHKH-KHWXYDKHSA-N methanesulfonyl chloride Chemical group C[35S](Cl)(=O)=O QARBMVPHQWIHKH-KHWXYDKHSA-N 0.000 claims 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 150000002901 organomagnesium compounds Chemical class 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003333 secondary alcohols Chemical class 0.000 claims 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims 1
- 235000019254 sodium formate Nutrition 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical group CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014075011 | 2014-04-09 | ||
| EP15776904.3A EP3129025B1 (en) | 2014-04-09 | 2015-04-08 | Process for the manufacturing of medicaments |
| PCT/CN2015/076083 WO2015154674A1 (en) | 2014-04-09 | 2015-04-08 | Process for the manufacturing of medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191306T1 true HRP20191306T1 (hr) | 2019-10-18 |
Family
ID=54287327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191306TT HRP20191306T1 (hr) | 2014-04-09 | 2019-07-18 | Postupak proizvodnje lijekova |
Country Status (22)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2866086C (en) * | 2012-03-01 | 2020-06-09 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015085007A1 (en) | 2013-12-06 | 2015-06-11 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| KR20200038553A (ko) * | 2014-04-09 | 2020-04-13 | 제넨테크, 인크. | 약제의 제조 방법 |
| DK3374359T3 (da) | 2015-11-09 | 2020-03-30 | Astrazeneca Ab | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer |
| JP2019518426A (ja) | 2016-04-15 | 2019-07-04 | ジェネンテック， インコーポレイテッド | がんの診断及び治療方法 |
| CA3073073A1 (en) | 2017-09-08 | 2019-03-14 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3546447A1 (en) * | 2018-03-29 | 2019-10-02 | Heidelberg Pharma GmbH | Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives |
| IL293382A (en) * | 2019-12-05 | 2022-07-01 | Astrazeneca Ab | Process and intermediates for the manufacture of formula (i) |
| CN115710158A (zh) * | 2021-08-23 | 2023-02-24 | 凯特立斯（深圳）科技有限公司 | 一种不对称催化制备替格瑞洛中间体的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| PL2001849T3 (pl) * | 2006-03-29 | 2015-04-30 | Hoffmann La Roche | Pochodne pirydyny i pirymidyny jako antagoniści mGluR2 |
| JP2011503006A (ja) * | 2007-11-06 | 2011-01-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌性複素環アミン |
| CA2866086C (en) * | 2012-03-01 | 2020-06-09 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| US9867667B2 (en) * | 2014-02-27 | 2018-01-16 | Canon Usa Inc. | Placement apparatus |
| KR20200038553A (ko) * | 2014-04-09 | 2020-04-13 | 제넨테크, 인크. | 약제의 제조 방법 |
-
2015
- 2015-04-08 KR KR1020207009606A patent/KR20200038553A/ko not_active Application Discontinuation
- 2015-04-08 CN CN202010547624.0A patent/CN111777594B/zh active Active
- 2015-04-08 TW TW108130327A patent/TWI762806B/zh active
- 2015-04-08 MX MX2016013162A patent/MX2016013162A/es active IP Right Grant
- 2015-04-08 CN CN201580029835.2A patent/CN106659721B/zh active Active
- 2015-04-08 SG SG11201608421XA patent/SG11201608421XA/en unknown
- 2015-04-08 BR BR112016023391-3A patent/BR112016023391B1/pt active IP Right Grant
- 2015-04-08 EP EP15776904.3A patent/EP3129025B1/en active Active
- 2015-04-08 KR KR1020167030901A patent/KR102490955B1/ko active IP Right Grant
- 2015-04-08 MX MX2020010384A patent/MX2020010384A/es unknown
- 2015-04-08 RU RU2016139286A patent/RU2684102C2/ru active
- 2015-04-08 NZ NZ725450A patent/NZ725450A/en unknown
- 2015-04-08 ES ES15776904T patent/ES2733495T3/es active Active
- 2015-04-08 CA CA2945098A patent/CA2945098C/en active Active
- 2015-04-08 AR ARP150101063A patent/AR099989A1/es unknown
- 2015-04-08 KR KR1020227045548A patent/KR20230006043A/ko active IP Right Grant
- 2015-04-08 EP EP19152874.4A patent/EP3494971B1/en active Active
- 2015-04-08 MY MYPI2021005412A patent/MY196320A/en unknown
- 2015-04-08 BR BR122020014933A patent/BR122020014933B8/pt active IP Right Grant
- 2015-04-08 WO PCT/CN2015/076083 patent/WO2015154674A1/en active Application Filing
- 2015-04-08 AU AU2015245743A patent/AU2015245743B2/en active Active
- 2015-04-08 PL PL15776904T patent/PL3129025T3/pl unknown
- 2015-04-08 CN CN202011466648.XA patent/CN112645927A/zh active Pending
- 2015-04-08 TW TW104111317A patent/TWI678366B/zh active
- 2015-04-08 SI SI201530799T patent/SI3129025T1/sl unknown
- 2015-04-08 MY MYPI2016001816A patent/MY188526A/en unknown
- 2015-04-08 CA CA3167641A patent/CA3167641A1/en active Pending
- 2015-04-08 JP JP2016561841A patent/JP6723926B2/ja active Active
-
2016
- 2016-10-05 US US15/285,781 patent/US20170022183A1/en not_active Abandoned
- 2016-10-06 IL IL248205A patent/IL248205B/en active IP Right Grant
- 2016-10-13 ZA ZA2016/07066A patent/ZA201607066B/en unknown
-
2018
- 2018-01-10 US US15/866,899 patent/US10611753B2/en active Active
-
2019
- 2019-07-18 HR HRP20191306TT patent/HRP20191306T1/hr unknown
- 2019-08-08 US US16/535,752 patent/US11098028B2/en active Active
- 2019-08-13 IL IL26869019A patent/IL268690A/en unknown
- 2019-12-18 US US16/718,602 patent/US11066389B2/en active Active
-
2020
- 2020-03-02 JP JP2020035010A patent/JP6974524B2/ja active Active
- 2020-08-21 AU AU2020220208A patent/AU2020220208B2/en active Active
-
2021
- 2021-06-22 JP JP2021102810A patent/JP2021167321A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191306T1 (hr) | Postupak proizvodnje lijekova | |
| US10513506B2 (en) | 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)pyridin-3-yl and processes of preparation | |
| IL269694A (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidine-2(H1)-one and processes for their preparation | |
| JP6633539B2 (ja) | ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程 | |
| CZ293135B6 (cs) | Použití alfa-substituované pyrimidin-thioalkylové nebo alkyletherové sloučeniny pro léčení HIV pozitivních jednotlivců | |
| Bannwarth et al. | Flexible synthesis of pyrimidines with chiral monofluorinated and difluoromethyl side chains | |
| US9890128B2 (en) | Process for making substituted quinazoline compounds | |
| JP2013534223A5 (US07321065-20080122-C00020.png) | ||
| US20220281861A1 (en) | Process For Preparing Aminopyrimidine Derivatives | |
| RS54309B1 (en) | DIHYDROETHORPHINS AND THEIR PREPARATION | |
| EP1104762A1 (en) | Substituted imidazo 1,2a]azines as selective inhibotors of cox-2 | |
| BR112021011330A2 (pt) | Processo farmacêutico e intermediários | |
| CN101611004B (zh) | 制备2-取代的-5-((1-烷基硫基)烷基)吡啶的方法 | |
| DK153401B (da) | 4-halogen-6-hydroxy-2h-pyran-3(6h)-on-forbindelser til anvendelse som mellemprodukter ved fremstilling af gamma-pyroner og fremgangsmaade til fremstilling af mellemprodukt-forbindelserne | |
| CN102115476A (zh) | 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法 | |
| CN109983004A (zh) | 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(5-巯基-1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈及制备方法 | |
| Alinezhad et al. | One-pot regioselective synthesis of 4-bromopyrazole derivatives under solvent free conditions | |
| CN105980354A (zh) | 有害生物防治剂的制造方法及其中间体 | |
| CN112645871B (zh) | N-cf2h-1,2-二氢吡啶-2-酮化合物的合成方法 | |
| WO2017091453A1 (en) | Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts | |
| CN103044393B (zh) | 一种1-(3-氯-2-吡啶基)-1h-吡唑-5-甲酸酯的合成方法 | |
| TWI450904B (zh) | 製備去氧呋喃核糖之方法 | |
| CN106187873B (zh) | 一种芳胺基烷基氧类化合物及其制备方法 | |
| CN104788272B (zh) | 二羰基芳香化合物及其制备方法和二羰基芳香组合物以及异噁唑化合物的制备方法 | |
| CN103739606A (zh) | 2-氨基-5,8-二取代[1,2,4]三唑[1,5-c]嘧啶的环保合成方法 |
